No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group

Tamara Castaño-Bonilla, Pau Montesinos, Claudia Sargas et al.|Disease Markers|2022

Cited by 2